Candel Therapeutics, Inc. (CADL) Earnings Call Transcripts
Candel Therapeutics, Inc.'s Latest Earnings Call - May 15, 2026
In Q1 2026, Candel Therapeutics presented extended follow-up data from their Phase III trial for aglatimagene besadenovec in localized prostate cancer. Revenue and earnings were not disclosed in the call. The key highlight was the statistically significant improvement in disease-free survival (DFS) with aglatimagene, suggesting a potential shift in treatment paradigms. Management plans to file a BLA in Q4 2026, indicating a strategic focus on regulatory approval. The trial results may influence stock movement due to the promising clinical outcomes and potential market impact.
Reported metrics
| Metric | Value |
|---|---|
| Disease-Free Survival Improvement | 39% improvement (beat) |
| Pathological Complete Response | Significant improvement (beat) |
| Time to Metastasis | 90% improvement (beat) |
| Adverse Events | Lower in aglatimagene arm (beat) |
Guidance from management
Candel plans to file a BLA for aglatimagene in Q4 2026. The guidance was maintained with a focus on regulatory approval and market introduction.
What management said
Yes. I'll just say this, Dr. Finkelstein. I want to thank you for sharing not only your scientific and medical insights, but also a very personal story here. So over to you, Dr. George. Please share your background and your thoughts about the data that we've shared today.
Thank you so much, Dr. George. We may come back to that last point later on. So let's move on to Dr. Shore. Maybe you can introduce yourself, your background and share your views on what was presented today at the AUA?
What analysts pressed on
Analysts questioned the comparative efficacy of aglatimagene versus surgical options and the potential shift in treatment paradigms. Concerns were also raised about the long-term data and its impact on metastasis-free survival.
Main topics on the call
- Phase III Trial Results — The Phase III trial showed a statistically significant improvement in DFS for patients treated with aglatimagene plus standard of care radiotherapy compared to placebo. This was supported by secondary endpoints, includin...
- Regulatory Pathway — Candel plans to file a BLA in Q4 2026. The trial was conducted under a Special Protocol Assessment with the FDA, and aglatimagene has received Fast Track and RMAT designations.
- Market Potential — Aglatimagene could become the first new therapy for localized prostate cancer in over 20 years, potentially transforming treatment approaches and reducing the need for salvage therapies.
- Safety Profile — Aglatimagene was generally well tolerated with fewer serious adverse events compared to placebo. Common side effects were low-grade and self-limited.
Read the full Candel Therapeutics, Inc. transcript (May 15, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Candel Therapeutics, Inc.
Candel Therapeutics, Inc. (CADL) is a publicly listed company in the Biotechnology industry, within the Health Care sector. It trades on NasdaqGM and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 2 calls on record spanning January 19, 2023 to May 15, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 2 Candel Therapeutics, Inc. earnings call transcripts on record, spanning January 19, 2023 to May 15, 2026. The most recent call on file is dated May 15, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- CADL
- Exchange
- NasdaqGM
- Country
- US
- Sector
- Health Care
- Industry
- Biotechnology
- Calls on record
- 2
- First call
- January 19, 2023
- Most recent
- May 15, 2026
| Quarter | Date | |
|---|---|---|
| Special Calls | May 15, 2026 | Read transcript → |
| Company Conference Presentations | Jan 19, 2023 | Read transcript → |